The DOI matches its Crossref record; 179 of the 179 references it cites were found in a registry or an index.
Metabotropic Glutamate Receptor Subtypes as Targets for Neuroprotective Drugs
Open accessAbstract
Metabotropic glutamate (mGlu) receptors have been considered as potential targets for neuroprotective drugs, but the lack of specific drugs has limited the development of neuroprotective strategies in experimental models of acute or chronic central nervous system (CNS) disorders. The advent of potent and centrally available subtype-selective ligands has overcome this limitation, leading to an extensive investigation of the role of mGlu receptor subtypes in neurodegeneration during the last 2 years. Examples of these drugs are the noncompetitive mGlu1 receptor antagonists, CPCCOEt and BAY-36-7620; the noncompetitive mGlu5 receptor antagonists, 2-methyl-6-(phenylethynyl)pyridine, SIB-1893, and SIB-1757; and the potent mGlu2/3 receptor agonists, LY354740 and LY379268. Pharmacologic blockade of mGlu1 or mGlu5 receptors or pharmacologic activation of mGlu2/3 or mGlu4/7/8 receptors produces neuroprotection in a variety of in vitro or in vivo models. MGlu1 receptor antagonists are promising drugs for the treatment of brain ischemia or for the prophylaxis of neuronal damage induced by synaptic hyperactivity. MGlu5 receptor antagonists may limit neuronal damage induced by a hyperactivity of N-methyl-d-aspartate (NMDA) receptors, because mGlu5 and NMDA receptors are physically and functionally connected in neuronal membranes. A series of observations suggest a potential application of mGlu5 receptor antagonists in chronic neurodegenerative disorders, such as amyotrophic lateral sclerosis and Alzheimer disease. MGlu2/3 receptor agonists inhibit glutamate release, but also promote the synthesis and release of neurotrophic factors in astrocytes. These drugs may therefore have a broad application as neuroprotective agents in a variety of CNS disorders. Finally, mGlu4/7/8 receptor agonists potently inhibit glutamate release and have a potential application in seizure disorders. The advantage of all these drugs with respect to NMDA or AMPA receptor agonists derives from the evidence that mGlu receptors do not “mediate,” but rather “modulate” excitatory synaptic transmission. Therefore, it can be expected that mGlu receptor ligands are devoid of the undesirable effects resulting from the inhibition of excitatory synaptic transmission, such as sedation or an impairment of learning and memory.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
D’Onofrio, M., Cuomo, L., Battaglia, G., Ngomba, R. T., Storto, M., Kingston, A. E., Orzi, F., Blasi, A. D., Iorio, P. D., Nicoletti, F., et al. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.00435.x · Cited by 126
Self-citationRetractedThe functional anatomy of basal ganglia disorders
Albin, R. L., Young, A. B., & Penney, J. B. (1989) · Trends in Neurosciences · doi:10.1016/0166-2236(89)90074-x · Cited by 5,353
Choi, D. W. (1992) · Journal of Neurobiology · doi:10.1002/neu.480230915 · Cited by 2,314
The metabotropic glutamate receptors: Structure and functions
Pin, J.-P., & Duvoisin, R. (1995) · Neuropharmacology · doi:10.1016/0028-3908(94)00129-g · Cited by 2,266
Molecular diversity of the NMDA receptor channel
Kutsuwada, T., Kashiwabuchi, N., Mori, H., Sakimura, K., Kushiya, E., Araki, K., Meguro, H., Masaki, H., Kumanishi, T., Arakawa, M., et al. (1992) · Nature · doi:10.1038/358036a0 · Cited by 1,344
Structural basis of glutamate recognition by a dimeric metabotropic glutamate receptor
Kunishima, N., Shimada, Y., Tsuji, Y., Sato, T., Yamamoto, M., Kumasaka, T., Nakanishi, S., Jingami, H., & Morikawa, K. (2000) · Nature · doi:10.1038/35039564 · Cited by 1,249
Shigemoto, R., Kinoshita, A., Wada, E., Nomura, S., Ohishi, H., Takada, M., Flor, P. J., Neki, A., Abe, T., Nakanishi, S., et al. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-19-07503.1997 · Cited by 1,116
Self-citationHomer: a protein that selectively binds metabotropic glutamate receptors
Brakeman, P. R., Lanahan, A. A., O'Brien, R., Roche, K., Barnes, C. A., Huganir, R. L., & Worley, P. F. (1997) · Nature · doi:10.1038/386284a0 · Cited by 1,114
The changing landscape of ischaemic brain injury mechanisms
Lee, J.-M., Zipfel, G. J., & Choi, D. W. (1999) · Nature · doi:10.1038/399a007 · Cited by 1,102 · cited 3×
“The coexistence of different processes of neuronal death must be outlined because the same therapeutic intervention that protects against necrotic death can aggravate apoptosis by trophic deprivation and vice versa (Lee et al., 1999).”
BackgroundResultInfluentialPharmacological agents acting at subtypes of metabotropic glutamate receptors
Schoepp, D. D., Jane, D. E., & Monn, J. A. (1999) · Neuropharmacology · doi:10.1016/s0028-3908(99)00092-1 · Cited by 1,060
Cited by
Mechanisms, challenges and opportunities in stroke
Lo, E. H., Dalkara, T., & Moskowitz, M. A. (2003) · Nature Reviews Neuroscience · doi:10.1038/nrn1106 · Cited by 1,781
Retinal ischemia: mechanisms of damage and potential therapeutic strategies
Osborne, N. N., Casson, R. J., Wood, J. P. M., Chidlow, G., Graham, M., & Melena, J. (2004) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2003.12.001 · Cited by 1,056
Mechanisms of ischemic brain damage
Doyle, K. P., Simon, R. P., & Stenzel-Poore, M. P. (2008) · Neuropharmacology · doi:10.1016/j.neuropharm.2008.01.005 · Cited by 902
Astrocyte dysfunction in neurological disorders: a molecular perspective
Seifert, G., Schilling, K., & Steinhäuser, C. (2006) · Nature Reviews Neuroscience · doi:10.1038/nrn1870 · Cited by 799
Neuroprotection for ischemic stroke: Past, present and future
Ginsberg, M. D. (2008) · Neuropharmacology · doi:10.1016/j.neuropharm.2007.12.007 · Cited by 779
Metadata
- Authors
- Bruno, V., Battaglia, G., Copani, A., D'Onofrio, M., Di Iorio, P., De Blasi, A., Melchiorri, D., Flor, P. J., & Nicoletti, F.
- Venue
- Journal of Cerebral Blood Flow & Metabolism
- Publisher
- SAGE Publications
- Published
- 2001-09
- Volume
- 21
- Issue
- 9
- Pages
- 1013-1033
- ISSN
- 0271-678X (ISSN-L)
- 1559-7016
- OpenAlex
- W2017505808
- Cited by
- 311
- References
- 179
- FWCI
- 7.08
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Metabotropic Glutamate Receptor Subtypes as Targets for Neuroprotective Drugs. https://app.cochat.ai/papers/10.1097/00004647-200109000-00001
- The paper
- Bruno, V., Battaglia, G., Copani, A., D'Onofrio, M., Di Iorio, P., De Blasi, A., Melchiorri, D., Flor, P. J., & Nicoletti, F. (2001). Metabotropic Glutamate Receptor Subtypes as Targets for Neuroprotective Drugs. Journal of Cerebral Blood Flow & Metabolism. https://doi.org/10.1097/00004647-200109000-00001
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.